Binx point-of-care STI test cleared for men

By LabPulse.com staff writers

April 30, 2020 -- Binx Health's point-of-care binx io molecular diagnostic instrument enabling rapid testing and reporting of sexually transmitted infections (STIs) has now been cleared by the U.S. Food and Drug Administration (FDA) for use in men.

The FDA previously cleared the company's rapid chlamydia and gonorrhea tests for women in 2019. The rapid test can provide results while patients are in the office and can help those with a positive STI test receive prompt treatment.

Binx is positioning the testing platform as the fastest, dual-gender test-and-treat system for two of the most common STIs.

As COVID-19 crisis continues, other infectious diseases threaten
While the world remains focused on the coronavirus pandemic, other emerging infectious diseases are also circulating and are public health threats. Shara...
Binx point-of-care STI testing clears FDA
Binx Health's point-of-care binx io molecular diagnostic instrument enabling rapid testing and reporting of sexually transmitted infections (STIs) in...
STD test market grows with incidence, new tech
The need to make screening and testing of sexually transmitted diseases (STDs) more accessible worldwide is creating opportunities for manufacturers of...

Copyright © 2020 LabPulse.com

Last Updated np 4/30/2020 4:38:48 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current